Pain Profiling

How it works

Risks & contraindications

Comparisons

Evidence quality

Highlighted claims

• The study distinguishes nociceptive, neuropathic, and nociplastic pain mechanisms using the International Association for the Study of Pain classification. — Strengthening and Targeted Rehabilitation for Optimal Neuromuscular Gains for chronic BACK pain (STRONG-BACK): protocol for a randomised controlled trial in participants with primary nociceptive pain drivers
• Nociceptive pain is linked to tissue damage or inflammation, while neuropathic and nociplastic pain have different drivers. — Strengthening and Targeted Rehabilitation for Optimal Neuromuscular Gains for chronic BACK pain (STRONG-BACK): protocol for a randomised controlled trial in participants with primary nociceptive pain drivers
• Pain mechanism distinctions matter because different mechanisms may respond differently to treatment. — Strengthening and Targeted Rehabilitation for Optimal Neuromuscular Gains for chronic BACK pain (STRONG-BACK): protocol for a randomised controlled trial in participants with primary nociceptive pain drivers
• The PDDM is used to identify dominant biopsychosocial drivers of pain and disability. — Strengthening and Targeted Rehabilitation for Optimal Neuromuscular Gains for chronic BACK pain (STRONG-BACK): protocol for a randomised controlled trial in participants with primary nociceptive pain drivers
• The LSIQ is used as a predictive tool for identifying patients likely to benefit from motor control and core exercise. — Strengthening and Targeted Rehabilitation for Optimal Neuromuscular Gains for chronic BACK pain (STRONG-BACK): protocol for a randomised controlled trial in participants with primary nociceptive pain drivers
• People with nociplastic pain, abnormal nociceptive processing, or substantial unhelpful beliefs may respond poorly to motor control and strengthening approaches. — Strengthening and Targeted Rehabilitation for Optimal Neuromuscular Gains for chronic BACK pain (STRONG-BACK): protocol for a randomised controlled trial in participants with primary nociceptive pain drivers